Kathleen I. Pritchard
#54,209
Most Influential Person Now
Candadian oncologist
Kathleen I. Pritchard's AcademicInfluence.com Rankings
Kathleen I. Pritchardmedical Degrees
Medical
#1026
World Rank
#1319
Historical Rank
Oncology
#64
World Rank
#68
Historical Rank
Download Badge
Medical
Why Is Kathleen I. Pritchard Influential?
(Suggest an Edit or Addition)According to Wikipedia, Kathleen I. Pritchard, is the head of oncology at Sunnybrook Health Sciences Centre in Toronto, Canada, specializing in breast cancer therapies, and leading the clinical trials division of the centre. She has authored numerous studies on women's health, breast cancer, hormone replacement therapy, public health, and research methodology. According to Thomson Reuters, Pritchard was one of the most cited researchers in the world in 2014 and 2015.
Kathleen I. Pritchard's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
- Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence (2007) (3911)
- Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
- Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. (2012) (2045)
- Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer (2018) (1273)
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. (2010) (1260)
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. (2012) (1142)
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. (2015) (1097)
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer (2003) (1091)
- Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. (2005) (1044)
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. (2002) (1006)
- Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer (1997) (882)
- A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. (2004) (880)
- 20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years (2017) (840)
- Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. (2007) (684)
- Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. (2002) (655)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) (639)
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. (2011) (618)
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. (1998) (612)
- The global breast cancer burden: variations in epidemiology and survival. (2005) (558)
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
- HER2 and responsiveness of breast cancer to adjuvant chemotherapy. (2006) (537)
- Risk of menopause during the first year after breast cancer diagnosis. (1999) (533)
- Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. (2005) (515)
- The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. (1995) (495)
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer (1994) (483)
- Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. (2017) (473)
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. (2014) (459)
- Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. (2007) (418)
- Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study (2010) (414)
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2013) (391)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2018) (353)
- Regional Nodal Irradiation in Early-Stage Breast Cancer. (2015) (350)
- Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. (2009) (345)
- Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study (2002) (325)
- Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. (2006) (318)
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. (2016) (317)
- Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. (1999) (311)
- Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. (2011) (309)
- Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. (1996) (297)
- Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. (2006) (293)
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. (2019) (269)
- NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. (2011) (266)
- Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. (2009) (264)
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. (2016) (261)
- Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. (2005) (243)
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial (2009) (224)
- A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen (2012) (223)
- Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. (2003) (221)
- Insulin-lowering effects of metformin in women with early breast cancer. (2008) (219)
- Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. (2013) (211)
- Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. (2005) (209)
- Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. (2008) (206)
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. (2016) (205)
- Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. (2009) (202)
- Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. (2010) (199)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. (2012) (190)
- Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. (2002) (188)
- Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents (2011) (186)
- Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. (2008) (179)
- Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker (2013) (178)
- HER-2 and topoisomerase II as predictors of response to chemotherapy. (2008) (173)
- A Comparison of Risk Perception and Psychological Morbidity in Women with Ductal Carcinoma in situ and Early Invasive Breast Cancer (2003) (167)
- Cancer treatment-induced bone loss in breast and prostate cancer. (2008) (167)
- Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback. (1998) (166)
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. (2011) (161)
- Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. (2000) (147)
- NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. (2006) (147)
- Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. (2015) (145)
- Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data. (2003) (145)
- Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. (2014) (143)
- Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial (2012) (141)
- Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. (2006) (137)
- Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. (2004) (137)
- Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. (2010) (137)
- Baseline staging tests in primary breast cancer: a practice guideline. (2001) (137)
- Defining breast cancer intrinsic subtypes by quantitative receptor expression. (2015) (136)
- Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. (2007) (135)
- Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. (2008) (133)
- Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. (2005) (130)
- Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer. (2013) (128)
- Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. (2013) (127)
- Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5. (2005) (126)
- Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer (2008) (116)
- Multidisciplinary weight management in locoregional breast cancer: results of a phase II study (1998) (115)
- Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. (2010) (113)
- Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes (2002) (111)
- The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. (2004) (111)
- Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. (2010) (111)
- Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. (2006) (109)
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. (2002) (108)
- First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. (2011) (108)
- High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome (2009) (107)
- Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. (1986) (107)
- Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. (2015) (105)
- Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables. (2004) (105)
- Tamoxifen therapy in premenopausal patients with metastatic breast cancer. (1980) (105)
- Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. (2012) (105)
- Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. (2007) (103)
- American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. (2009) (103)
- Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. (2013) (101)
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 (2014) (101)
- Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. (1997) (101)
- Is tamoxifen effective in prevention of breast cancer? (1998) (96)
- Diet and breast cancer: evidence that extremes in diet are associated with poor survival. (2003) (93)
- Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial (2013) (92)
- Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial (2006) (92)
- Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. (1996) (91)
- Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. (2011) (91)
- HER2/neu in systemic therapy for women with breast cancer: a systematic review (2008) (90)
- Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008 300(23):2754-64. PMID: 19088353 (2009) (89)
- Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. (2014) (89)
- American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. (2003) (89)
- Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. (2012) (88)
- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. (2009) (86)
- Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. (2003) (86)
- Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) (2010) (85)
- Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. (2013) (85)
- Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. (2008) (85)
- Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? (2005) (84)
- Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. (2012) (84)
- The effect of melatonin on sleep and quality of life in patients with advanced breast cancer (2016) (82)
- Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer (2011) (82)
- Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. (2012) (81)
- Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
- Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. (2008) (79)
- Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making. (1997) (77)
- Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. (2017) (76)
- Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of respon (2010) (75)
- Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. (2013) (73)
- Body radiation exposure in breast cancer radiotherapy: impact of breast IMRT and virtual wedge compensation techniques. (2006) (72)
- Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials (2013) (69)
- An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer (1997) (67)
- Serum Lipids and Outcome of Early-stage Breast Cancer: Results of a Prospective Cohort Study (2005) (66)
- Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. (2016) (65)
- Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer (2002) (65)
- Biological Significance of Occult Micrometastases in Histologically Negative Axillary Lymph Nodes in Breast Cancer Patients Using the Recent American Joint Committee on Cancer Breast Cancer Staging System (2006) (64)
- Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. (2012) (64)
- A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. (2009) (63)
- Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. (2008) (63)
- Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis (2018) (62)
- Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. (2014) (60)
- Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients (2018) (59)
- Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. (2015) (58)
- Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. (2006) (58)
- Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. (2004) (57)
- Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. (2011) (56)
- Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. (2008) (56)
- Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? (1996) (55)
- Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study (2016) (54)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and Woman's Place. (1999) (54)
- Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. (2013) (54)
- Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture (2014) (54)
- Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC). (2013) (54)
- Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial (2011) (54)
- Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. (1997) (53)
- A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. (2010) (53)
- DTIC therapy in metastatic malignant melanoma: a simplified dose schedule. (1980) (53)
- Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. (2009) (52)
- First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study (2012) (52)
- Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment. (1987) (51)
- Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial (2014) (49)
- Prognostic factors affecting the natural history of node-negative breast cancer (2004) (49)
- CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. (2012) (48)
- A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. (2014) (48)
- Endocrine therapy: is the first generation of targeted drugs the last? (2013) (48)
- Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. (2016) (47)
- Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET). (2016) (47)
- Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2014) (46)
- Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. (2014) (45)
- Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies (2016) (45)
- A priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative Ultrasound (2017) (45)
- Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. (1998) (44)
- A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1 (1997) (44)
- Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial (2011) (43)
- Adjuvant targeted therapy in early breast cancer (2009) (42)
- Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. (2020) (42)
- Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities (2017) (42)
- S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial. (2011) (42)
- Randomized trial of group psychosocial support in metastatic breast cancer: the BEST study. Breast-Expressive Supportive Therapy study. (1996) (41)
- Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. (2015) (41)
- Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. (1987) (41)
- Obesity and hormone therapy in breast cancer: an unfinished puzzle. (2010) (40)
- A randomized trial of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (asct) compared to standard chemo therapy (ct) in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) clinical trials group study (2001) (39)
- Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? (2009) (39)
- Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials (2022) (39)
- Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials. (2008) (39)
- Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues (2006) (39)
- Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study (2014) (38)
- Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient (2006) (37)
- Endocrine therapy of advanced disease: analysis and implications of the existing data. (2003) (37)
- Platinum-based chemotherapy in triple-negative advanced breast cancer (2014) (37)
- Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). (2006) (36)
- A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12). (2010) (36)
- Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. (2009) (36)
- Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach (2016) (36)
- Combining endocrine agents with chemotherapy: Which patients and what sequence? (2008) (35)
- Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial (2014) (34)
- Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada. (2019) (34)
- Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma. (1981) (34)
- Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift? (2002) (34)
- Frequency of vitamin D (Vit D) deficiency at breast cancer (BC) diagnosis and association with risk of distant recurrence and death in a prospective cohort study of T1–3, N0–1, M0 B (2008) (34)
- Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. (1993) (33)
- Adjuvant Therapy for Node-Negative Breast Cancer (1989) (33)
- Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ? (2004) (33)
- Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial. (2009) (32)
- Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials (2018) (32)
- The use of endocrine therapy. (1989) (31)
- Droloxifene, a new antiestrogen: Its role in metastatic breast cancer (2004) (30)
- Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19 (2006) (30)
- Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening? (2020) (30)
- Attitudes of Canadian Oncology Practitioners Toward Psychosocial Interventions in Clinical and Research Settings in Women With Breast Cancer (1997) (30)
- Optimizing the management of HER2-positive early breast cancer: the clinical reality. (2010) (30)
- Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study. (1986) (30)
- A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. (1992) (30)
- Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) (2017) (29)
- Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. (1990) (29)
- Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy (2015) (28)
- Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications (2014) (27)
- Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women (2005) (27)
- Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? (2011) (26)
- Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial (2008) (26)
- The Head to Head trial: Letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. (2006) (26)
- Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer? (2009) (26)
- Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis. (2017) (26)
- The best use of adjuvant endocrine treatments. (2003) (25)
- Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. (2002) (25)
- Adjuvant therapy of the very young woman. (2007) (25)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. (1998) (25)
- A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21) (2007) (25)
- Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases (2018) (25)
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. (2014) (25)
- Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. (2012) (24)
- Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial (2011) (24)
- Keeping faith with trial volunteers (2007) (23)
- Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. (2013) (23)
- Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy (2020) (23)
- Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines (2011) (22)
- Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience. (2013) (22)
- Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. (2013) (22)
- The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives. (2001) (22)
- Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. (2016) (22)
- Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. (2003) (22)
- Abstract S1-1: Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast Cancer (2010) (22)
- Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials (2017) (22)
- Activity of fulvestrant in HER2-overexpressing advanced breast cancer. (2010) (21)
- The efficacy of bone scanning in the follow-up of patients with operable breast cancer (2005) (21)
- Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen. (2005) (21)
- Hormone replacement in women with a history of breast cancer. (2001) (21)
- NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. (2011) (21)
- Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada. (2016) (20)
- Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer (2015) (20)
- Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: will it play in Peoria? (2001) (20)
- Preferential Killing of Breast Tumor Initiating Cells by N,N-Diethyl-2-[4-(Phenylmethyl)Phenoxy]Ethanamine/Tesmilifene (2009) (20)
- The impact of a breast cancer diagnosis in young women on their relationship with their mothers. (2014) (20)
- Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2− advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy (2013) (20)
- Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results. (2011) (20)
- Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study (2019) (20)
- The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer (2009) (20)
- 1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2 (2014) (20)
- ABREAST: A new global registry of adjuvant strategies in patients with early stage breast cancer (2005) (19)
- A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: A comparison of primary care versus specialist care. (2004) (19)
- Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations. (2009) (19)
- Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients (2009) (19)
- Current and future directions in medical therapy for breast carcinoma (2000) (18)
- A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. (2016) (18)
- Have we been guilty of ageism in the primary treatment of breast cancer? (2007) (18)
- Ascertaining Prognosis for Breast Cancer in Node‐Negative Patients with Innovative Survival Analysis (2006) (18)
- Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. (2014) (18)
- Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. (2010) (17)
- Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27 (2018) (17)
- Overdiagnosing overdiagnosis. (2014) (17)
- Can improved communication increase patient participation in randomised clinical trials? (2001) (17)
- Systemic adjuvant therapy for node-negative breast cancer: proven or premature? (1989) (17)
- Disseminated tumor embolism from breast cancer leading to multiorgan failure. (2010) (17)
- Screening for endometrial cancer: is it effective? (1989) (17)
- Review of the clinical studies using the 21-gene assay. (2010) (17)
- A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium. (2016) (17)
- Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. (2018) (16)
- Adjuvant endocrine therapies for pre-/perimenopausal women. (2005) (16)
- Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab (2018) (16)
- An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays (1996) (16)
- Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. (2018) (16)
- Menopausal estrogen replacement therapy in women with breast cancer (1995) (16)
- Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies (2022) (16)
- Breast cancer prevention with selective estrogen receptor modulators: a perspective. (2001) (16)
- Selective Application of Axillary Node Dissection in Elderly Women with Early Breast Cancer (2007) (16)
- Liver metastases: can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management? (1997) (16)
- Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. (2009) (16)
- A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer (2005) (15)
- The standardization of estrogen receptors (1993) (15)
- Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials (2013) (15)
- Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. (2011) (15)
- Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). (2009) (15)
- Breast Cancer Prevention with Selective Estrogen Receptor Modulators (2001) (15)
- 18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer (2015) (15)
- The Henrietta Banting Breast Centre database: a model for clinical research utilizing a hospital-based inception cohort. (1995) (14)
- Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer. (1984) (14)
- Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. (2016) (14)
- Final results of a meta-analysis testing HER2 and topoisomerase IIα genes as predictors of incremental benefit from anthracyclines in breast cancer. (2010) (14)
- Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor‐Induced Arthralgias: An Analysis of CCTG MA.27 (2018) (13)
- Competing risks of death in younger and older postmenopausal breast cancer patients. (2014) (13)
- NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer (2008) (13)
- Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study? (1999) (13)
- TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients (2012) (13)
- The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers (2009) (13)
- Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer. (2017) (13)
- Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines (2009) (13)
- Cardiovascular Health and Aromatase Inhibitors (2012) (13)
- Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor–positive breast cancer: NCIC CTG MA.27 (2017) (12)
- Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada (2019) (12)
- Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis. (2007) (12)
- Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study (2018) (12)
- Should observational studies be a thing of the past? (2008) (12)
- Breast Cancer Research and Treatment 2001 Reviewers (2004) (12)
- Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis (2015) (12)
- TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. (2018) (11)
- Hormonal replacement therapy in breast cancer. (2002) (11)
- The prognostic effect of lipids on early-stage breast cancer (BC) outcome (2005) (11)
- Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial (2008) (11)
- A priori prediction of breast tumour response to chemotherapy using quantitative ultrasound imaging and artificial neural networks (2019) (11)
- Role of gonadotropin-releasing hormone analog in the management of male metastatic breast cancer is uncertain. (2007) (11)
- A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis (2001) (11)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 4: Urogenital atrophy, vasomotor instability, sleep disorders, and related symptoms. (1999) (11)
- The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer (2020) (11)
- Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27 (2016) (11)
- Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. (2015) (10)
- Ovarian ablation as adjuvant therapy for early-stage breast cancer. (1998) (10)
- Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference (2008) (10)
- First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in >2000 Patients (Pts). (2009) (10)
- neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part II. (2003) (10)
- Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience. (2006) (10)
- Tamoxifen Response - a Useful Guide to Subsequent Treatment in Premenopausal Patients with Metastatic Breast-Cancer (1980) (10)
- Endocrine therapy for breast cancer. (2000) (10)
- Estrogen/hormone replacement therapy and the etiology of breast cancer. (1998) (10)
- The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studies. (2006) (10)
- The fox guarding the clinical trial: internal vs. external validity in randomized studies (1999) (9)
- A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32). (2011) (9)
- Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32 (2017) (9)
- Personalized medicine: what exactly is it and can we truly measure it? (2012) (9)
- Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer? (2010) (9)
- Clinical trial update: National Cancer Institute of Canada (2005) (9)
- Treatment-Emergent Symptoms and the Risk of Breast Cancer Recurrence in the NCIC CTG MA.27 Adjuvant Aromatase Inhibitor Trial. (2009) (9)
- Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial (2016) (9)
- Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. (2011) (9)
- Phase i ii study of flutamide in metastatic breast cancer (1986) (9)
- Current status of adjuvant endocrine therapy for resectable breast cancer. (1987) (9)
- An improved statistical approach: can it clarify the role of new prognostic factors for breast cancer? (1996) (9)
- A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. (2007) (8)
- 253 Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial (2012) (8)
- Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. (1992) (8)
- Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2. (2013) (8)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar's Head Inn, Charlottesville, Virginia, September 21-23, 1997. (1999) (8)
- Long-term follow-up of women in trials of adjuvant therapy for breast cancer: is it still important? (2011) (8)
- S4-7: Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2-Overexpressing Breast Cancer. (2011) (8)
- Optimal chemotherapy for women with breast cancer: the plot thickens. (2003) (8)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 2: Hormone replacement therapy and breast cancer. (1999) (8)
- Breast cancer: the real challenge (1997) (7)
- The role of the taxanes in the management of metastatic breast cancer (2003) (7)
- Abstract PD4-02: Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies (2020) (7)
- Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets). (2012) (7)
- Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). (2021) (7)
- Adjuvant therapy for breast cancer: we are solving the puzzle, but pieces are still missing. (2007) (7)
- Plasma vascular endothelial growth factor as a predictive biomarker: Door closed? (2017) (7)
- Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort (2013) (7)
- Breast Cancer Screening: Beyond Mortality (2019) (7)
- Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): Subpopulation analysis of the MO19391 study. (2009) (7)
- A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials (2015) (7)
- A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial. (2013) (6)
- Is exercise effective in reducing the risk of breast cancer in postmenopausal women? (2004) (6)
- 5017 Multinational study (n = 2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391 (2009) (6)
- Estimating per patient funding for cancer clinical trials: an Ontario based survey. (2005) (6)
- Abstract PD5-07: The impact of early lapatinib-induced rash on disease-free and overall survival in patients treated within the ALTTO phase III randomized trial (2016) (6)
- Use of elevated bone turnover to predict bone metastasis (2008) (6)
- Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC). (2013) (6)
- Endocrine symptoms to predict risk of recurrence? (2008) (6)
- Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. (2003) (6)
- Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. (2019) (6)
- Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC). (2009) (6)
- The Canadian Experience with Intensive Fluorouracil, Epirubicin and Cyclophosphamide in Patients with Early Stage Breast Cancer (2012) (5)
- A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22 (2015) (5)
- Should Tamoxifen Be Used to Treat Premenopausal Women with Breast Cancer? (2000) (5)
- Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement (2006) (5)
- Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen (2005) (5)
- Population-based evaluation of 21-gene assay in treatment decision making for early breast cancer in Ontario. (2014) (5)
- Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2. (2012) (5)
- Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial. (2010) (5)
- The use of oral BCG in the treatment or metastatic malignant melanoma. (1976) (5)
- The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. (2011) (5)
- S35 CEF versus CMF in premenopausal women — Recent update (1998) (5)
- The role of bisphosphonates in early- and advanced-stage breast cancer: have we finally optimized care? (2015) (5)
- Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). (2014) (5)
- Safety and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): Analysis of MO19391 according to CT. (2016) (5)
- Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. (2016) (5)
- Tamoxifen (T) compared to placebo (P), after adjuvant chemotherapy (CT), in premenopausal women with early breast cancer (EBC): Interim results of NCIC-CTG MA.12 (2007) (5)
- Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience (2020) (5)
- The clinical practice guideline: an evolving health care technology. (1997) (5)
- Abstract P2-16-06: Final Overall Survival Results, Including Analysis of Patients with Triple-Negative Disease and Aged ≥70 Years, from the ATHENA Study Evaluating First-Line Bevacizumab-Containing Therapy for Locally Recurrent/Metastatic Breast Cancer (2010) (4)
- Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial. (2011) (4)
- Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2. (2013) (4)
- Patterns of trastuzumab (T) use in three Canadian provinces. (2004) (4)
- New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17. (2016) (4)
- The Early Breast Cancer Trialists Collaborative Group (EBCTCG) Process: Is it Still Relevant in 2006? (2006) (4)
- Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2. (2012) (4)
- Tamoxifen and Metastatic Breast Cancer (1978) (4)
- The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer: Lammers LA, Mathijssen RHJ, van Gelder T, et al (Univ Hosp, Rotterdam, The Netherlands) Br J Cancer 103:765-771, 2010§ (2011) (4)
- Optimizing the delivery of targeted research: an opportunity for comparative effectiveness research. (2010) (4)
- The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. (2020) (4)
- Duplication of Chromosome 17 CEP Predicts for Anthracycline Benefit: A Meta-Analysis of 4 Trials. (2009) (4)
- Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29 (2015) (4)
- A prospective study evaluating 18F-Fluorodeoxyglucose (18FDG) positron emission tomography (PET) in the assessment of axillary nodal spread in women undergoing sentinel lymph node biopsy (SLNB) for breast cancer (2008) (4)
- Abstract P2-08-01: Prospective trial of endocrine therapy alone in patients with estrogen receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry (2016) (4)
- A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer (2019) (4)
- 2123 POSTER MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC) (2007) (4)
- Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. (2016) (4)
- Tamoxifen-associated hot flashes in women. (2007) (4)
- Raloxifene: handle with care. (2001) (4)
- Systemic adjuvant therapy for node-negative breast cancer. (1989) (4)
- The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients. (2001) (4)
- The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer (2020) (4)
- MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC) (2008) (4)
- Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer (1990) (3)
- Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (2017) (3)
- A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors. (2010) (3)
- Abstract P2-13-02: Effect of aspirin (ASP) or celecoxib (CC) use on outcomes in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27 (2012) (3)
- Adjuvant endocrine therapy for breast cancer: longer therapy and the need for personalized treatment--should we treat beyond the data? (2013) (3)
- Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence. (2016) (3)
- Efficacy and Safety of Everolimus in Postmenopausal Women With Advanced Breast Cancer (BOLERO-2): Effect of Visceral Metastases and Prior Endocrine Therapy (2012) (3)
- Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact? (2006) (3)
- Bone-Targeted Therapy in Early Breast Cancer. (2018) (3)
- Phase I-II study of DalCM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC) (2005) (3)
- Association of young age and chemotherapy with psychosocial distress and health-related quality of life (HRQOL) during the first year after breast cancer (BC). (2004) (3)
- Endocrine Therapy of Advanced Disease (2003) (3)
- Activity of fulvestrant in HER 2-overexpressing advanced breast cancer (2010) (3)
- Subgroup analysis of a phase III trial of doxorubicin vs doxorubicin plus tesmilifene in advanced breast cancer (ABC): Tesmilifene survival benefit focused on patients with more aggressive disease (2005) (3)
- An update on adjuvant systemic therapy for elderly patients with early breast cancer (2016) (3)
- Bisphosphonates: are they standard of care for the treatment of breast cancer? (2007) (3)
- Cost-effectiveness analysis of oncotype DX-guided treatment in early breast cancer. (2016) (3)
- 3LBA Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial (2012) (3)
- P4-12-05: Impact of the Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA) Weight Loss Intervention upon Physical Activity. (2011) (3)
- Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study (2020) (3)
- Association of young age and chemotherapy with psychosocial distress and health-related quality of life (HRQOL) during the first year after breast cancer (BC) (2004) (3)
- Adjuvant endocrine therapy of breast cancer. (1992) (3)
- Symptoms and cancer outcome in adjuvant endocrine therapy for breast cancer: why are they associated? (2013) (3)
- Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369. (2013) (3)
- The Role of Tamoxifen in Premenopausal Women with Metastatic Carcinoma of the Breast - An Update (1981) (3)
- Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919). (2011) (3)
- Clinical management and resolution of stomatitis in BOLERO-2. (2013) (3)
- ABC 1 (1st International consensus guidelines for advanced breast cancer): a positive step. (2012) (3)
- Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer (1997) (3)
- The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous? (2016) (2)
- A Phase II Study (FINDER 2) Comparing Three Dosing Regimens of Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer. (2009) (2)
- Patterns of antidepressant use among women initiating tamoxifen therapy for the treatment of breast cancer in Ontario, Canada. (2010) (2)
- Impact of concurrent (CON) and sequential (SEQ) radiotherapy (RT) with adjuvant aromatase inhibitors (AI) in early-stage breast cancer (EBC): NCIC CTG MA.27. (2012) (2)
- Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer. (2011) (2)
- Update of the oxford overview: new insight and perspectives in the era of personalized medicine. (2012) (2)
- Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29. (2012) (2)
- Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. (2011) (2)
- Abstract P6-01-10: Prognostic significance of breast cancer index (BCI) in node-positive hormone receptor positive early breast cancer: NCIC CTG MA.14 (2015) (2)
- The Influence of Tamoxifen On Menstruation and Serum Hormone Levels in Premenopausal Patients with Metastatic Breast-Cancer (1981) (2)
- CLINICAL USES OF BAYESIAN PROBABILITY (1985) (2)
- Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study (2020) (2)
- Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial. (2012) (2)
- Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer (2003) (2)
- A review of exemestane in the management of breast cancer (2005) (2)
- Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC). (2014) (2)
- A randomized controlled trial (RCT) of long-term follow-up for early stage breast cancer comparing family physician to specialist care: A report of secondary outcomes. (2006) (2)
- Commentary: anthracyclines in early-stage breast cancer: is it the end of an era? (2009) (2)
- LBA7DISEASE-FREE SURVIVAL (DFS) IN THE LAPATINIB ALONE ARM AND EXPANDED RESULTS OF THE PHASE III ALTTO TRIAL (BIG 2-06; NCCTG (ALLIANCE) N063D) IN THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER (EBC) (2014) (2)
- Impact of the 21-gene Recurrence Score assay on the adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes in an academic centre in Ontario. (2016) (2)
- Risk of chemotherapy induced menopause: more detailed data will lead to improved quality of life. (2007) (2)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 1: Defining the problem. Proceedings of a conference held at the Boar's Head Inn Charlottesville, Virginia. September 21-23, 1997. (1999) (2)
- An update on treatment for post-menopausal metastatic breast cancer in elderly patients (2018) (2)
- High levels of uPA and PAI-1 predict a good response to anthracyclines (2010) (2)
- Antihormone therapy in recurrent metastatic breast cancer. (2008) (2)
- Abstract P6-08-04: The Impact of a Breast Cancer Diagnosis in Young Women on their Relationship with their Mothers (2012) (2)
- Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. (2014) (2)
- Earlier Detection and Diagnosis of Breast Cancer : Recommendations and Scientific Review from It ’ s About Time ! (2010) (2)
- P5-14-01: Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis. (2011) (1)
- Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases (2018) (1)
- Optimal endocrine therapy (2001) (1)
- GnRH analogues and ovarian ablation: their integration in the adjuvant strategy. (1998) (1)
- Tailored targeted therapy for all: a realistic and worthwhile objective against (2009) (1)
- Clinical cooperative trials of the national cancer institute of Canada clinical trials group breast cancer site group (1994) (1)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 3: Prevention of osteoporosis and CV effects of estrogens and antiestrogens. (1999) (1)
- Sex hormones and breast cancer: the issue of hormone replacement. (1996) (1)
- 178PGENERATION OF A PLASMA MICRORNA (MIRNA) SIGNATURE PREDICTING RESPONSE TO METRONOMIC CHEMOTHERAPY (MC) FOR ADVANCED BREAST CANCER (ABC). (2014) (1)
- Influenza vaccine effectiveness among cancer patients: A population-based study using health administrative and laboratory testing data from Ontario, Canada. (2018) (1)
- Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. (2010) (1)
- Bisphosphonates for prevention of bone loss in women with early breast cancer (2009) (1)
- Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy? (2011) (1)
- Erratum to: Platinum-based chemotherapy in triple-negative advanced breast cancer (2015) (1)
- 213 Duplication of chromosome 17 CEP predicts for anthracycline benefit: evidence from an international meta-analysis of 4 adjuvant breast cancer trials for the HER2/TOP2A meta-analysis study group (2010) (1)
- 0068 Elevated bone resorption predicts shorter recurrence-free survival (RFS) for bone metastasis in breast cancer (BC) (2009) (1)
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: Results From BOLERO-2 (2015) (1)
- P46 Patterns of recurrence and prognosis in women with basal-like breast cancer (2007) (1)
- Bisphosphonates for prevention of bone loss in women with early breast cancer (2009) (1)
- Informed consent in compliance studies. (1993) (1)
- Arm lymphedema in breast cancer patients: Is it always related to treatment (2004) (1)
- Abstract P3-09-02: Association between definitive surgery and times to administration of adjuvant chemotherapy and outcomes in early breast cancer: Analysis of adjuvant studies conducted by NCIC Clinical Trials Group (NCIC CTG) (2015) (1)
- Adjuvant Breast Cancer Treatment : Evolution or Revolution ? (2005) (1)
- Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole. (2013) (1)
- Aromatase inhibitors as adjuvant therapy: how will results of the ATAC trial at San Antonio 2004 and BIG 1-98 at St Gallen 2005 impact on aromatase inhibitors as adjuvant endocrine therapy? (2005) (1)
- Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. (2012) (1)
- Abstract P5-14-01: A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer (2016) (1)
- Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort. (2011) (1)
- Virtual wedge and intensity modulated radiotherapy reduce the magnitude of scattered radiation during adjuvant breast radiation (2004) (1)
- Tamoxifen for breast cancer prevention (2000) (1)
- Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study. (2012) (1)
- Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings. (2009) (1)
- Abstract P2-09-16: Effect of Continuous Statistically Standardized qPCR and IHC ER and PR on Disease-Free Survival in NCIC CTG MA.12 (2010) (1)
- Pharmacokinetic analysis of tamoxifen metabolites in premenopausal women with early breast cancer: A substudy of NCIC CTG MA.12 randomized clinical trial. (2014) (1)
- Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl). (2014) (1)
- Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial (2014) (1)
- Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort (2013) (1)
- 5BA Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry (2015) (1)
- Dementia risk among post-menopausal women treated with endocrine therapy for early-stage breast cancer in Ontario, Canada. (2020) (1)
- HBV screening before adjuvant chemotherapy in patients with early breast cancer: A cost-effectiveness analysis. (2014) (1)
- P1-06-08: Effect of Treatment Emergent Symptoms on Relapse Free Survival: NCIC CTG MA.12 a Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women in Early Breast Cancer. (2011) (1)
- Abstract P5-07-01: Successful whole transcriptome analysis of 25-year-old breast tumor samples from the phase III trial SWOG-8814 by next generation sequencing (NGS): Standardized analytical methods for exploratory and validation studies (2016) (1)
- Extended adjuvant therapy: the role of subset analyses. (2017) (1)
- Obesity, patient characteristics, and TIMP-1: Effects on non-bone RFS in NCIC CTG MA.14. (2010) (1)
- Abstract P4-09-09: Serum SDF-1: Biomarker of Bone Relapse in the NCIC MA.14 Adjuvant Breast Cancer Trial (2010) (1)
- Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study (2012) (0)
- Are routine secondary pathology reviews still necessary in the management of ductal carcinoma in situ (2003) (0)
- Early prediction of therapy responses and outcomes in breast cancer patients using textural characteristics of quantitative ultrasound spectral parametric maps (2014) (0)
- Examination of TIMP-1 Levels and Relapse-Free Survival for Patients in NCIC CTG MA.14 Who Received Adjuvant Tamoxifen +/- Octreotide LAR. (2009) (0)
- 415 Comparison of two Phase II trials evaluating three dosing regimens of fulvestrant in Japanese vs non-Japanese postmenopausal women with advanced breast cancer (FINDER1 and FINDER2) (2010) (0)
- Patients and Methods Patient Selection (2003) (0)
- S35 Adjuvant treatment of the very young woman (2007) (0)
- Guidelines, consensus conferences and overviews (meta-analysis). (2009) (0)
- Abstract P3-10-26: Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort (2010) (0)
- Abstract P2-12-03: A pilot study evaluating the benefits and feasibility of an exercise program for breast cancer patients receiving adjuvant chemotherapy. (2012) (0)
- A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas. (2014) (0)
- Abstract 3787: Thyroid hormone induced proliferation of breast cancer cell lines: A novel approach to hormone therapy (2016) (0)
- Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective? (2008) (0)
- COGNITIVE SEQUELAE OF ADJUVANT ENDOCRINE THERAPY FOR THE TREATMENT OF BREAST CANCER IN OLDER WOMEN: A FEASIBILITY STUDY (2016) (0)
- Commentary (Wong/Pritchard): Adjuvant Hormonal Therapy in Early Breast Cancer (2005) (0)
- 221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO (2020) (0)
- Adjuvant hormonal therapy for premenopausal breast cancer: incorporating clinical experience. (2010) (0)
- Abstract PD7-07: Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer – new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814 (2017) (0)
- Reductions in tumor RNA integrity associated with clinical response to epirubicin/docetaxel chemotherapy in breast cancer patients. (2009) (0)
- Obesity and cancer: The risks, science, and potential management strategies: Commentary (2005) (0)
- BCG in the treatment of cancer. (1983) (0)
- Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab (2017) (0)
- Abstract 1679: Identification of pharmacogenomic markers associated with paclitaxel and carboplatin response in cancer: The cross-talk between agents (2010) (0)
- Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14 (2016) (0)
- Abstract 601: Cognitive sequelae of adjuvant endocrine therapy in older women treated for early-stage breast cancer (2018) (0)
- Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2. (2013) (0)
- landmarks Reports of recent research Report from the Canadian Association of Medical Oncology Annual Scientific Meeting side effects the rOLe Of ObserVatiONaL studies iN medicaL ONcOLOgy research (2016) (0)
- Abstract P2-09-14: Association between BMI and residual estradiol levels in post-menopausal women using adjuvant letrozole: Results of a prospective study (2017) (0)
- Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies. (2016) (0)
- Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The Canadian cancer trials group (NCIC CTG) MA.21 experience. (2016) (0)
- Correction: Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach (2017) (0)
- Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials (2021) (0)
- Hepatitis B virus screening before adjuvant chemotherapy in patients with early stage breast cancer: A cost-effectiveness analysis. (2015) (0)
- Adjuvant therapy for early breast cancer: where do we stand today? (2003) (0)
- 158PDAdjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06) (2017) (0)
- Validated or not validated? That is the question. (2014) (0)
- A study of surveillance mammography (SM) of the contralateral breast (CLB) following total mastectomy (TM) for breast cancer (BC) (2005) (0)
- Reply to P. Ameri et al (2012) (0)
- BOLERO-2: Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive ADVANCED breast cancer refractory to letrozole or anastrozole (2011) (0)
- Risk o f M enopause D uring t he F irst Y ear A fter B reast Cancer D iagnosis (1999) (0)
- SY-5-2 Selection of treatment (1996) (0)
- Identification of cancer care and protocol characteristics associated with recruitment rate in breast cancer clinical trials in Ontario (2007) (0)
- Adjuvant endocrine therapy in postmenopausal breast cancers. Discussions (2003) (0)
- Risk o f A cute L eukemia F ollowing E pirubicin-Based A djuvant Chemotherapy: A R eport F rom t he N ational C ancer I nstitute o f Canada C linical T rials G roup (2003) (0)
- Abstract P3-11-01: An updated systematic review and meta-analysis of the safety and efficacy of phosphoinositide 3-kinase inhibitors (PI3Ki) in advanced breast cancer (2020) (0)
- Abstract P4-01-03: Withdrawn (2019) (0)
- The effect of trastuzumab on pCR in locally advanced HER2-positive breast cancer. (2011) (0)
- Hormone Replacement Therapy After Breast Cancer (2006) (0)
- Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy (2015) (0)
- Treatment of Advanced Breast-Cancer (1981) (0)
- Fast ing Insul in and Outcome in Early-Stage Breast Cancer : Resul ts of a Prospect i ve Cohort Study (2001) (0)
- Future direction panel discussion (2001) (0)
- Does adjuvant radiation therapy benefit women with small mammography-detected breast cancers? (2017) (0)
- P1-06-07: TIMP-1 in Combination with HER2 and TOP2A for Prediction of Benefit from Adjuvant Anthracyclines in High Risk Breast Cancer Patients. (2011) (0)
- Abstract P5-12-02: Effect of 5 vs 2.5 mg/day letrozole on residual estrogen levels in post-menopausal women with high BMI - A prospective crossover study (2016) (0)
- F a s t i n g I n s u l i n and O utcome i n E arly-Stage B reast Cancer: R esults o f a P rospective C ohort S tudy (2002) (0)
- Update of the Oxford Overview: New Insight and Perspectives in the Era of Personalized Medicine (2012) (0)
- tor family targeting agents in breast cancer may be justified. (2012) (0)
- Commentary (Pritchard): Current Status of Vinorelbine For Breast Cancer (1995) (0)
- Abstract P5-08-08: Risk reducing mastectomy in average and high risk patients with locally advanced triple negative breast cancer (2020) (0)
- Treatment of Estrogen Deficiency Symptoms in Women (2017) (0)
- Adjuvant endocrine therapy for breast cancer: a commentary. (2012) (0)
- Abstract 3586: Reactive oxygen species and antioxidant pathway in resistance to doxorubicin and paclitaxel in cancer (2010) (0)
- BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer. (2012) (0)
- Predictors of adherence among post-menopausal women receiving adjuvant endocrine therapy for breast cancer in Ontario, Canada (2019) (0)
- How recruiting patients to clinical trials affects the doctor/patient relationship (2002) (0)
- Abstract S3-02: Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – Transcriptome expression analysis of the phase III trial SWOG-8814 (2016) (0)
- Chemotherapy and endocrine therapy in metastatic disease. (1989) (0)
- Prognostic and Predictive Impact of Intrinsic Biological Classification by Immunohistochemistry (IHC) and QPCR for Adjuvant Tamoxifen in Pre-Menopausal Breast Cancer: Results from the NCIC CTG MA.12 Trial. (2009) (0)
- P5-17-06: Pilot Study of a Questionnaire To Assess Impact of a Breast Cancer Diagnosis in Young Women on Their Relationship with Their Mothers. (2011) (0)
- Abstract P1-07-13: Prognostic relevance of statistically standardized estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in tamoxifen(TAM)-treated NCIC CTG MA.14 patients (2012) (0)
- Abstract P2-10-01: Validation that a histone gene signature predicts anthracycline response in early breast cancer (2018) (0)
- A phase I/II study of increasing doses of epirubicin (E) and docetaxel (D) plus pegfilgrastim (Pegf) for locally advanced (LABC) or inflammatory breast cancer (IBC): NCIC CTG MA.22. (2010) (0)
- P4-01-04: Effects of CYP2D6 Phenotype and Drug Adherence on Tamoxifen Metabolite Levels. (2011) (0)
- Tamoxifen versus aromatase inhibitors for the adjuvant treatment of breast cancer in older women: A feasibility study to examine differences in cognitive outcomes. (2016) (0)
- Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methothrexate, and daily prednisone (DalCMP) as therapy for metastatic breast cancer (MBC). (2010) (0)
- Abstract P2-05-05: A four gene signature predicts anthracycline benefit: Evidence from the BR9601 and MA5 breast cancer trials (2015) (0)
- Expression of thyroid hormone receptor alpha (THRα) isoforms in triple negative breast cancer (TNBC). (2015) (0)
- Abstract P4-10-29: Identifying novel molecular markers of response to trastuzumab in metastatic breast cancer (2020) (0)
- JNCCN NCCN Task Force Report : Adjuvant Therapy for Breast Cancer — Clarification and Expansion of NCCN Clinical Practice Guidelines (2006) (0)
- Prospective change in 25-OH vitamin D levels over long-term follow-up and health outcomes in breast cancer survivors. (2010) (0)
- Abstract P4-01-01: Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial (2014) (0)
- Lapatinib in HER2+ early breast cancer: Quality of life analysis. (2012) (0)
- Abstract PD6-04: Lifestyle intervention study (LISA) in early breast cancer (BC): An RCT of the effects of a telephone-based weight loss intervention (with educational materials) vs educational materials alone on disease-free survival (DFS) (2019) (0)
- BCG in the treatment of cancer. (1983) (0)
- Vitamin D and aromatase inhibitor-induced arthralgia: Analysis of Canadian cancer trial group MA.27 data. (2016) (0)
- Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study (2022) (0)
- Adjuvant T reatment a nd O nset o f M enopause P redict W eight Gain A fter B reast C ancer D iagnosis (1999) (0)
- The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada (2021) (0)
- Risk of Death Due to Breast Cancer in Women Treated with Selective Serotonin Reuptake Inhibitor Antidepressants and Tamoxifen. (2009) (0)
- P2-12-23: How Should We Assess Tumour Size (T Stage) in Patients with Multicentric/Multifocal Breast Cancer? Results from the NCIC CTG MA.5 Randomized Trial of CEF vs. CMF in Pre-Menopausal Women with Node Positive Breast Cancer. (2011) (0)
- Can we efficiently and safely combine a pan-class I phosphatidylinositol-3-kinase inhibitor with paclitaxel in metastatic breast cancer? (2017) (0)
- Abstract P2-10-04: Targeted sequencing in early breast cancer: Identification of novel candidate mutations predictive of anthracycline benefit (2018) (0)
- Nonclinical factors in patient selection for surgery (2001) (0)
- American S ociety o f C linical O ncology T echnology A ssessment Working G roup U pdate: U se o f A romatase I nhibitors i n t he Adjuvant S etting (2003) (0)
- 192P The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada (2020) (0)
- Commentary (Pritchard)—Obesity and Cancer: The Risks, Science, and Potential Management Strategies (2005) (0)
- The first 10 years experience with genetic testing (GT) for BRCA1/2 mutations in a publicly funded program at a tertiary care teaching hospital in Ontario, Canada. (2013) (0)
- Emission Tomography in the Assessment of Regional Nodal Spread of Disease in Patients With Breast Cancer: An Ontario Clinical Oncology Group Study (2012) (0)
- Abstract P4-01-12: The association of circulating tumor cells with tumor response in breast cancer patients undergoing neoadjuvant chemotherapy (2020) (0)
- Breast Cancer: Bone-Targeted Therapies (2018) (0)
- Diet a nd B reast C ancer: E vidence T hat E xtremes i n D iet A re Associated W ith P oor S urvival (2003) (0)
- Effect of adjuvant chemotherapy on bone resorption marker beta C-telopeptide (B-CTX) in postmenopausal women. (2016) (0)
- 12 Everolimus Added to Exemestane Reduced Bone Markers in Postmenopausal Women with Advanced Breast Cancer (ABC): the BOLERO-2 Trial (2012) (0)
- Final overall survival results and effect of prolonged (a parts per thousand yen1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial (2011) (0)
- 1122PFeasibility of routine collection of health state utilities using EQ-5D in a breast cancer outpatient clinic (2017) (0)
- Antihormone Therapy in Recurrent Metastatic Breast Cancer. Author's reply (2008) (0)
- The Validity of Summing Results of Clinical Trials in Breast Cancer (1987) (0)
- DELTA: A Randomized Trial of Decongestive Lymphatic Therapy for Women with Lymphedema following Treatment for Breast Cancer (2009) (0)
- How to Validate Histochemical Techniques as Predictors of Hormonal Response (2018) (0)
- Identifying research priorities in the treatment of patients with early breast cancer: from the patient perspective. (2019) (0)
- Adjuvant Therapy for Breast Cancer: A Summary of the Early Breast Cancer Trialists’ Collaborative Group (Oxford) Overview (1999) (0)
- Abstract P3-14-11: Microarray data analysis and long term outcomes of NCIC-CTG MA.22: Neoadjuvant epirubicin and docetaxel with pegfilgrastim support for locally advanced breast cancer (2013) (0)
- Abstract CT317: Quantitative ultrasound for personalized chemotherapy in locally advanced breast cancer: Clinical trial results (2015) (0)
- Reply to C. McCowan et al (2011) (0)
- P2-12-28: Studies of a Malignancy-Associated Protein, Osteopontin, in NCIC CTG MA.14, a Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR in Adjuvant Treatment of Women with Early Breast Cancer. (2011) (0)
This paper list is powered by the following services:
Other Resources About Kathleen I. Pritchard
What Schools Are Affiliated With Kathleen I. Pritchard?
Kathleen I. Pritchard is affiliated with the following schools:
